Malignant bowel obstruction in advanced cancer patients: epidemiology, management, and factors influencing spontaneous resolution

Albert Tuca, Ernest Guell, Emilio Martinez-Losada, Nuria Codorniu, Albert Tuca, Ernest Guell, Emilio Martinez-Losada, Nuria Codorniu

Abstract

Malignant bowel obstruction (MBO) is a frequent complication in advanced cancer patients, especially in those with abdominal tumors. Clinical management of MBO requires a specific and individualized approach that is based on disease prognosis and the objectives of care. The global prevalence of MBO is estimated to be 3% to 15% of cancer patients. Surgery should always be considered for patients in the initial stages of the disease with a preserved general status and a single level of occlusion. Less invasive approaches such as duodenal or colonic stenting should be considered when surgery is contraindicated in obstructions at the single level. The priority of care for inoperable and consolidated MBO is to control symptoms and promote the maximum level of comfort possible. The spontaneous resolution of an inoperable obstructive process is observed in more than one third of patients. The mean survival is of no longer than 4-5 weeks in patients with consolidated MBO. Polymodal medical treatment based on a combination of glucocorticoids, strong opioids, antiemetics, and antisecretory drugs achieves very high symptomatic control. This review focuses on the epidemiological aspects, diagnosis, surgical criteria, medical management, and factors influencing the spontaneous resolution of MBO in advanced cancer patients.

Keywords: bowel occlusion; cancer; intestinal obstruction; malignant bowel obstruction.

Figures

Figure 1
Figure 1
Physiopathology of MBO.

References

    1. Anthony T, Baron T, Mercadante S, et al. Report of the clinical protocol committee: development of randomized trials for malignant bowel obstruction. J Pain Symptom Manage. 2007;34(Suppl 1):S49–S59.
    1. Ripamonti C, Easson AM, Gerdes H. Management of malignant bowel obstruction. Eur J Cancer. 2008;44(8):1105–1115.
    1. Dvoretsky PM, Richards KA, Angel C, Rabinowitz L, Beecham JB, Bonfiglio TA. Survival time, causes of death, and tumor. Treatment related morbidity in 100 women with ovarian cancer. Hum Pathol. 1988;19(11):1273–1279.
    1. Baines M, Oliver DJ, Carter RL. Medical management of intestinal obstruction in patients with advanced malignant disease – a clinical and pathological study. Lancet. 1985;2(8462):990–993.
    1. Tuca A, Codorniu N, Garzón, Serrano G. Malignant bowel obstruction due to advanced cancer in palliative care: Observational and descriptive study. 5th Research Forum of European Association for Palliative Care; May 2008; Trodheim, Norway. Poster: 462.
    1. Miller G, Boman J, Shrier I, Gordon PH. Small bowel obstruction secondary to malignant disease: an 11-year audit. Can J Surg. 2000;43(5):353–358.
    1. Tuca A, Roca R, Sala C, et al. Efficacy of granisetron in the antiemetic control of nonsurgical intestinal obstruction in advanced cancer: a phase II clinical trial. J Pain Symptom Manage. 2009;37(2):259–270.
    1. Arvieux C, Laval G, Stefani L, Villard ML, Mestrallet JP, Cardin N. Protocol for the treatment of malignant inoperable bowel obstruction: a prospective study of 80 cases at Grenoble University Hospital Center. J Pain Symptom Manage. 2006;31(6):502–512.
    1. Blair SL, Chu DZ, Schwarz E. Outcome of palliative operations for malignant bowel obstruction in patients with peritoneal carcinomatosis from nongynecological cancer. Ann Surg Oncol. 2001;8(8):632–637.
    1. Ripamonti C, Twycross R, Baines M, et al. for Working Group of the European Association for Palliative Care. Clinical-practice recommendations for management of bowel obstruction in patients with end-stage cancer. Support Care Cancer. 2001;9(4):223–233.
    1. Bennett MI, Livingstone HJ, Costello P, Allen KR, Degg TJ. Symptom scores, serotonin and 5-hydroxyindole acetic acid levels in cancer patients with and without bowel obstruction. Palliat Med. 2007 Mar;21(2):157–159.
    1. Jimenez-Garcıa A, Balongo-Garcıa R, Alconero FF, et al. Intestinal wall damage in simple ileus in rabbits: immune modulator role of somatostatine. Hepatogastroenterology. 2004;51(58):1030–1036.
    1. Goyal RK, Hirano I. Enteric nervous system. N Engl J Med. 1996;334(17):1106–1115.
    1. Helye L, Easson AM. Surgical Approaches to Malignant Bowel Obstruction. J Support Oncol. 2008;6(3):105–113.
    1. Branco BC, Barmparas G, Schnüriger B, Inaba K, Chan LS, Demetriades D. Systematic review and meta-analysis of the diagnostic and therapeutic role of water-soluble contrast agent in adhesive small bowel obstruction. Br J Surg. 2010;97(4):470–478.
    1. Suri S, Gupta S, Sudhakar PJ, Venkataramu NK, Sood B, Wig JD. Comparative evaluation of plain films, ultrasound and CT in the diagnosis of intestinal obstruction. Acta Radiol. 1999;40(4):422–428.
    1. Thompson WM, Kilani RK, Smith BB, et al. Accuracy of abdominal radiography in acute small bowel obstruction: does reviewer experience matter? AJR Am J Roentgenol. 2007;188(3):W233–W238.
    1. de Bree E, Koops W, Kröger R, van Ruth S, Witkamp AJ, Zoetmulder MA. Peritoneal carcinomatosis from colorectal or appendiceal origin: correlation of preoperative CT with intraoperative findings and evaluation of interobserver agreement. J Surg Oncol. 2004;86(2):64–73.
    1. Jacquest P, Jelinek JS, Steves MA, Sugarbaker PH. Evaluation of computed tomography in patients with peritoneal carcinomatosis. Cancer. 1993;72(5):1631–1636.
    1. Low R, Chen S, Barone R. Distinguishing benign from malignant bowel obstruction in patients with malignancy: findings at MR imaging. Radiology. 2003;228(1):157–165.
    1. Beall D, Fortman B, Lawler B, Regan F. Imaging bowel obstruction: a comparison between fast magnetic resonance imaging and helical computed tomography. Clin Radiol. 2002;57(8):719–724.
    1. Ha HK, Shin BS, Lee SI, et al. Usefulness of CT in patients with intestinal obstruction who have undergone abdominal surgery for malignancy. AJR Am J Roentgenol. 1998;171(6):1587–1593.
    1. Chan A, Woodruf RK. Intestinal obstruction in patients with wide-spread intra- abdominal malignancy. J Pain Symptom Manage. 1992;7(6):339–342.
    1. Lau PV, Lorenz PG. Results of surgery for malignant bowel obstruction in advanced, unresectable, recurrent colorectal cancer. Dis Colon Rectum. 1993;36(1):61–64.
    1. Jong P, Sturgeon J, Jamieson CG. Benefit of palliative surgery for bowel obstruction in advanced ovarian cancer. Can J Surg. 1995;38(5):454–457.
    1. Yazdi GP, Miedema BW, Humphrey LJ. High mortality after abdominal operation in patients with large volume malignant ascites. J Surg Oncol. 1996;62(2):93–96.
    1. Woolfson RG, Jennings K, Whalen GF. Management of bowel obstruction in patients with abdominal cancer. Arch Surg. 1997;132(10):1093–1097.
    1. Sun X, Li X. Management of bowel obstruction in advanced ovarian cancer: an analysis of 57 cases. Zhonghua Zhong Liu Za Zhi. 1995;17(1):39–42.
    1. Tekkis P, Kinsman R, Thompsom M, Stamatakis J. The Association of Coloproctology of Great Britain and Ireland study of large bowel obstruction caused by colorectal cancer. Ann Surg. 2004;240(1):76–81.
    1. Bryan D, Radbod R, Berek J. An analysis of surgical versus a chemotherapeutic intervention for the management of intestinal obstruction in advanced ovarian cancer. Int J Gynecol Cancer. 2006;16(1):125–134.
    1. Parker MC, Baines MJ. Intestinal obstruction in patients with advanced malignant disease. Br J Surg. 1996;83(1):1–2.
    1. Feuer DJ, Broadley KE, Shepherd JH, Barton DP. Systematic review of surgery in malignant bowel obstruction in advanced gynecological and gastrointestinal cancer. Gynecol Oncol. 1999;75(3):313–322.
    1. Zoetmulder FA, Helmerhorst TJ, van Coevorden F, Wolfs PE, Leyer JP, Hart AA. Management of bowel obstruction in patients with advanced ovarıan cancer. Eur J Cancer. 1994;30A(11):1625–1628.
    1. Jeurnink SM, van Eijck CH, Steyerberg EW, Kuipers EJ, Siersema PD. Stent versus a gastrojejunostomy for the palliation of gastric outlet obstruction: a systematic review. BMC Gastroenterol. 2007;7:18.
    1. Dormann A, Meisner S, Verin N, Wenk Lang A. Self-expanding metal stents for gastroduodenal malignancies: systematic review of their clinical effectiveness. Endoscopy. 2004;36(60):543.
    1. Holt AP, Pate lM, Ahmed MM. Palliation of patients with malignant gastroduodenal obstruction with self-expanding metallic stents: the treatment of choice? Gastrointest Endosc. 2004;60(6):1010–1017.
    1. Watt AM, Faragher IG, Griffin TT, Rieger NA, Maddern GJ. Self-expanding Metallic Stents for Relieving Malignant Colorectal Obstruction: A Systematic Review. Ann Surg. 2007;246(1):24–30.
    1. Khot UP, Lang AW, Murali K, Parker MC. Systematic review of the efficacy and safety of colorectal stents. Br J Surg. 2002;89(9):1096.
    1. Campagnutta E, Cannizzaro R, Gallo A, et al. Palliative treatment of upper intestinal obstruction by gynecological malignancy: the usefulness of percutaneous endoscopic gastrostomy. Gynecol Oncol. 1996;62(1):103–105.
    1. Pothuri B, Montemrano M, Gerardi M, et al. Percutaneous endoscopic gastrostomy tube placement in malignat bowel obstruction due to ovarıan carcinoma. Gynecol Oncol. 2005;96:330–334.
    1. Fan BG. Parentera l nutrition prolongs the survival of patients associated with malignant gastrointestinal obstruction. JPEN J Parenter Enteral Nutr. 2007;31(6):508–510.
    1. Bozzetti F, Cozzaglio L, Biganzoli E, et al. Quality of life and length of survival in advanced cancer patients on home parenteral nutrition. Clin Nutr. 2002;21(4):281–288.
    1. World Health Organization. Cancer Pain Relief – with a guide to opioid availability. second edition. WHO; Geneva: 1996. [Accessed May 2012]. Available in internet: .
    1. Ventafridda V, Tamburini M, Caraceni A, De Conno F, Naldi F. A validation study of the WHO method for cancer pain relief. Cancer. 1987;59(4):850–856.
    1. Zech DF, Grond S, Lynch J, Hertel D, Lehmann KA. Validation of World Health Organization Guidelines for cancer pain relief: a 10-year prospective study. Pain. 1995;63(1):65–76.
    1. Mercadante S. Pain treatment and outcomes for patients with advanced cancer who receive follow-up care at home. Cancer. 1999;85(8):1849–1858.
    1. Hanks GW, Conno F, Cherny N, et al. for Expert Working Group of the Research Network of the European Association for Palliative Care. Morphine and alternative opioids in cancer pain: the EAPC recommendations. Br J Cancer. 2001;84(5):587–593.
    1. Riley J, Eisenberg E, Müller-Schwefe G, Drewes AM, Arednt-Nielsen L. Oxycodone: a review of its use in the management of pain. Curr Med Res Opin. 2008;24(1):175–192.
    1. Tassinari D, Sartori S, Tamburini E, et al. Transdermal fentanyl as a front-line approach to moderate-severe pain: a meta-analysis of randomized clinical trials. J Palliat Care. 2009;25(3):172–180.
    1. Laval G, Girardier J, Lassauumiere JM, Leduc B, Haond C, Schaerer R. The use of steroids in the management of inoperable intestinal obstruction in terminal cancer patients: do they remove the obstruction? Palliat Med. 2000;14(1):3–10.
    1. Hardy JR, Ling PJ, Mansi J, et al. Pitfalls in placebo controlled trials in palliative care: dexamethasone for the palliation of malignant bowel obstruction. Palliat Med. 1998;12(16):437–443.
    1. Neville R, Fielding P, Cambria RP, Modlin I. Vascular responsiveness in obstructed gut. Dis Colon Rectum. 1991;34(3):229–235.
    1. Nellgard P, Bojo L, Cassuto J. Importance of vasoactive intestinal peptide and somatostatin for fluid losses in small bowel obstruction. Scand J Gastroenterol. 1995;30(5):464–469.
    1. Ripamonti C, Mercadante S, Groff L, Zecca E, De Conno F, Cassucio A. Role of octreotide, scopolamine butylbromide and hydration in symptom control of patients with inoperable bowel obstruction having a nasogastric tube – a prospective, randomized clinical trial. J Pain Symptom Manage. 2000;19(1):23–34.
    1. Mercadante S, Ripamonti C, Casuccio A, Zecca E, Groff L. Comparison of octreotide and hyoscine butylbromide in controlling gastrointestinal symptoms due to malignant inoperable bowel obstruction. Support Care Cancer. 2000;8(3):188–191.
    1. Mercadante S, Casuccio A, Mangione S. Medical Treatment for inoperable malignant bowel obstruction: A qualitative systematic review. J Pain Symptom Manage. 2007;33(2):217–223.
    1. Watari H, Hosaka M, Wakui Y, et al. A Prospective Study on the Efficacy of Octreotide in the Management of Malignant Bowel Obstruction in Gynecologic Cancer. Int J Gynecol Cancer. Epub February 14, 2012.
    1. Hisanaga T, Shinjo T, Morita T, et al. Multicenter prospective study on efficacy and safety of octreotide for inoperable malignant bowel obstruction. Jpn J Clin Oncol. 2010 Aug;40(8):739–745.
    1. Laval G, Rousselot H, Toussaint-Martel S, et al. SALTO: a randomized, multicenter study assessing octreotide LAR in inoperable bowel obstruction. Bull Cancer. 2012 Feb 1;99(2):E1–E9.
    1. Mercadante S, Porzio G. Octreotide for malignant bowel obstruction: twenty years after. Crit Rev Oncol Hematol. Epub January 23, 2012.
    1. Clark K, Lam L, Currow D. Reducing gastric secretions-a role for histamine 2 antagonists or proton pump inhibitors in malignant bowel obstruction? Support Care Cancer. 2009 Dec;17(12):1463–1468.
    1. Clark K, Lam LT, Gibson S, Currow D. The effect of ranitidine versus proton pump inhibitors on gastric secretions: a meta-analysis of randomised control trials. Anaesthesia. 2009;64(6):652–657.
    1. [homepage on the Internet] Pallaitive Care. Practice Guidelines in Oncology of National Comprehensive Cancer Network. [Accessed February 19, 2011]. [Accessed May 2012]. .
    1. Tuca A, Martínez E, Güell E, Gómez Batiste X. Malignant bowel obstruction. Med Clin (Barc) 2010;135(8):375–381.
    1. Matulonis UA, Seiden MV, Roche M, et al. Long-acting octreotide for the treatment and symptomatic relief of bowel obstruction in advanced ovarian cancer. J Pain Symptom Manage. 2005;30(6):563–569.

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel